Repros Therapeutics, Inc. (RPRX)

[Stockexpertpro]

RPRX 3$ Call Options Fills at 3 Cents Cheap way to play the up coming ADCOM Today either you win big or lose buy 10 call options for what 30$ limits your risk w huge upside potential

[lecorb]

$5.50 price target. Shares Rally Following Ladenburg Upgrade To Buy, Positive Data

Shares of Repros Therapeutics Inc
RPRX 2.34%
climbed more than 8 percent in Wednesday’s pre-market hours after positive clinical data of Proellex led Ladenburg Thalmann to upgrade shares to Buy, with a $5.50 price target.
Repros announced positive Phase 2b data for both its oral and vaginal delivery trials following two 18-week cycles of treatment with Proellex in uterine fibroids.
Among others, the study met its primary endpoint of induction of amenorrhea for both pooled oral and vaginal delivery compared to placebo. The company plans to submit a request to the FDA before the end of 2016 to discuss the Phase 3 program......

http://www.benzinga.com/analyst-ratings/analyst-color/16/11/8707546/repros-therapeutics-shares-rally-following-ladenburg-upg

[TheKobra]

Oversold.

[TheKobra]

In @1.52 today. Ovesold.

[dave86]

I bought in today @ 2.15 lets see what happens.

[HandyMan2000]

ANNNNNNNND, WE'RE OFF AND RUNNING!!



$RPRX

[stocktrademan]

RPRX bullish 2.17



normal chart


log chart

[HandyMan2000]

NEWS OUT!!!!!!


CIRCUIT BREAKERS!!!


SHORT COVER PARTY TODAY


$RPRX

[HandyMan2000]

ALL ABOARD????



$RPRX

[HandyMan2000]

EVERYONE'S BOATS LOADED????


READY FOR TAKE-OFF!!!

$RPRX

[HandyMan2000]

WOW THIS COULD BE THE NEXT @DVX!!!!


CIRCUIT BREAKERS READY????



$RPRX

[stockdawg44]

Nice find, on a roll CS......

[$Pistol Pete$]

$RPRX Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis

Source: GlobeNewswire Inc.

Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided the results of the first course of treatment from Repros’ ongoing study of Proellex® for the treatment of premenopausal women with confirmed symptomatic endometriosis.
The study was a Phase 2, double-blind study of oral Proellex® (telapristone acetate) in a population of women with moderate to severe confirmed endometriosis defined as a baseline BBSS Score (Biberoglu and Behrman Symptom Score) of 7 or greater. Subjects were randomized to 6 or 12 mg of Proellex® or placebo in a 1:1:1 fashion. A course of treatment lasted 18 weeks and was followed by an Off Drug Interval. Subjects kept daily diaries recording assessments of pain, menstrual bleeding and analgesic use.

The study randomized 60 subjects, 13 in Argentina and 47 in the US. The subjects’ mean age was 30 years. As anticipated, 70% of subjects treated with Proellex® became amenorrheic. The induction of amenorrhea was associated with a substantial reduction in reported pain and subsequent reduction in analgesic use. Responses were similar across the two doses of Proellex® and are reported here pooled.

Subjects assessed menstrual and non-menstrual pain daily during baseline and treatment. The median percentage change from baseline in the patient BBSS assessment of menstrual pain showed that subjects improved with an 85.4% reduction in baseline score (p < 0.0001). In addition, despite evidence of a placebo response, subjects treated with Proellex® had a statistically significant greater reduction in menstrual pain compared to the 37.5% change from baseline achieved with placebo (p = 0.0008). Although non-menstrual pelvic pain was also reduced with treatment, a difference between treatment groups could not be detected.

Encouragingly, the improvement in menstrual pain translated to a reduction in the use of analgesics. During this first course of treatment, subjects treated with Proellex® experienced a 56% reduction in total pill count while placebo-treated subjects’ pill use declined by 30% (p = 0.0521). The reduction in non-prescription use was most striking: Proellex®-treated subjects had a 74% reduction while placebo-treated subjects only experienced a reduction of 11% (p = 0.0423).

Treatment with Proellex® was generally well tolerated.

Given these results, the Company is preparing to interact with the FDA to discuss plans for late stage development of Proellex® and Phase 3 studies to treat women who struggle with painful menses.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Forward-Looking Statements

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should” or similar expressions. These statements are based on assumptions that the Company has made in light of the Company’s experience in the industry, as well as the Company’s perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to the timing and nature of the results of clinical studies and the impact of such results. Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including risks that additional phases of clinical studies may not be successfully undertaken or completed, that the FDA may not ultimately approve the product candidate, the risk that any marketing approvals, if granted, may have significant limitations on use, that even if an NDA is approved, the Company may not be able to successfully commercialize the product candidate, risks relating to the Company’s ability to protect its intellectual property rights and such other risks as are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company’s website at http://www.reprosrx.com.


CONTACT:
Investor Relations:
Thomas Hoffmann
The Trout Group
[phone]
[e-mail]
Primary Logo

[ClearlyStocks]

RPRX $3.20

[ClearlyStocks]

RPRX $2.88 new highs

[ClearlyStocks]

RPRX $2.52 positive Phase 2

[ClearlyStocks]

RPRX $2.25

[ClearlyStocks]

RPRX $1.90 fly time

[stocktrademan]

RPRX bullish 2.01

[stocktrademan]

RPRX bullish 2.0499

[stocktrademan]

RPRX bullish 1.88

cup and handle pattern
https://www.google.com/search?q=cup+and+handle+pattern&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwjtp66R6ZjOAhXM5oMKHb4ECnEQsAQIJA&biw=2000&bih=958&dpr=0.8

[PAC]

RPRX 1.97 nice little move on higher vol out of bottom base. Might catch a bid today

[RandolRocketman]

Form 8-K REPROS THERAPEUTICS INC. For: Jul 19
BY 10K Wizard
— 4:12 PM ET 07/19/2016

[lowpsycho]

What's up with this why 10c drop? Following this but not as closely as I should.

[omri]

I really thought we would be higher than this..glta $$$$

[The Market Maker]

picked up a few shares

[omri]

I'm in!!$$$$$$glta

[omri]

Agree.. I will buy tomorrow as well $$$$

[68metal]

Got some yesterday, gonna pick more up first thing!!! This is ripe for a buyout....todays PR was a "for sale" ad IMO! Gonna be at 2.70-3.20 eod mañana no problem!

[Gatorelf]

Time for a bounce

[Jack30]

Huge short recovery today with big volume. With a good news, 1st it was up 50% pre-market, but shorts took over fast and pushed it down to recover as much possible. Look at the chart and is turning off of it's 30 days moving average. There is no more shares for recovery. We will see a huge reversal tomorrow and will go higher.

[Lone Wolf]

Wonder how the shorts are going to react. There's an 11% open position.

[Zorro]

$2.80 in AH trading. Could open over $3 tomorrow.

[Zorro]

Hope you held as things are looking up here IMO!

[ttboyoner]

What do you think of the upcoming earnings on this stock?? Do you think that will take great considerations on reaching there?

[europtiger]

Just bought back in today

[ClearlyStocks]

$RPRX big $2.30 pop might see $3+

[henrytrean]

Garbage stock

[cjf913913]

Looks like the nail was hit on the head there.......

Rprx

[aheckler1]

whos shortting? :)

[europtiger]

Lets See ;)

I dont have lots here,But so much fun to watch ;)

[Lone Wolf]

Squeeze is on like Donkey Kong!! Even in the AH!! Look at those big bids popping up here!!

[ClayTrader]

* * $RPRX Video Chart 04-19-16 * *

Link to Video - click here to watch the technical chart video

[Lone Wolf]

No more shares available here!!! Look out above!! LoLzzz

[OB_WEALTH_INC]

RPRX BREAKOUT $3.50!!! I AM GOING IN BIG $50,000 POSITION ...HAHAH LETS MAKE BIG $$$$$$ AGAIN!!!!!!!

[ClearlyStocks]

$3.34

[penny chaser]

The noose is tightening

[Lone Wolf]

Classic squeeze. Man you don't see these anymore....and boy do I miss them!

$RPRX

[ClearlyStocks]

Just as I said yesterday. Monster $3.20 gap

[OB_WEALTH_INC]

BREAKOUT ALERT AT $3.50. This still has gas to breakout today